{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:42:04Z","timestamp":1790361724532,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ijrobp.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T20:18:27Z","timestamp":1515529107000},"page":"1100-1118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group"],"prefix":"10.1016","volume":"100","author":[{"given":"Louis S.","family":"Constine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Milgrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. George","family":"Mikhaeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Illidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Dieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig H.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2018.01.011_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib2","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib3","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib4","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ijrobp.2018.01.011_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/annonc\/5.suppl_2.S101","article-title":"Early-stage Hodgkin's disease: Long-term results with radiotherapy alone or combined radiotherapy and chemotherapy","volume":"5","author":"Brusamolino","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib6","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib7","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferme","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib8","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18f]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib9","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","article-title":"Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma","volume":"16","author":"Hutchings","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib11","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib12","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: Nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000318885","article-title":"Meta-analyses of early-stage Hodgkin lymphoma","volume":"125","author":"Herbst","year":"2011","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib16","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group","volume":"20","author":"Josting","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib17","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 Years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib18","first-page":"467","article-title":"Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial","volume":"20","author":"Ferme","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib19","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib20","first-page":"CD009411","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib21","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant","volume":"54","author":"Arai","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib22","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijrobp.2015.02.008","article-title":"Expert radiation oncologist interpretations of involved-site radiation therapy guidelines in the management of Hodgkin lymphoma","volume":"92","author":"Hoppe","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib24","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib25","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET-Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/bjh.14902","article-title":"Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: Can residual PET-positive disease be cured with radiotherapy alone?","volume":"179","author":"Milgrom","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0360-3016(97)00352-0","article-title":"Salvage radiotherapy for Hodgkin's disease following chemotherapy failure","volume":"39","author":"Wirth","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib30","first-page":"1221","article-title":"Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease","volume":"26","author":"Kaplan","year":"1966","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib31","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib32","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","article-title":"Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up","volume":"80","author":"Vose","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib33","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0360-3016(95)00180-7","article-title":"Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed\/refractory Hodgkin's disease","volume":"33","author":"Mundt","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.radonc.2011.12.031","article-title":"Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma","volume":"103","author":"Biswas","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00277-5","article-title":"High-dose therapy and autologous bone marrow transplantation for relapsed\/refractory Hodgkin's disease: The impact of involved field radiotherapy on patterns of failure and survival","volume":"36","author":"Poen","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/01.coc.0000209370.61355.8e","article-title":"The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease","volume":"29","author":"Wendland","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.05.010","article-title":"Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed\/refractory Hodgkin lymphoma?","volume":"81","author":"Kahn","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib39","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.ijrobp.2012.04.007","article-title":"Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant","volume":"84","author":"Goda","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/COC.0b013e3182880b9f","article-title":"Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"38","author":"Eroglu","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib41","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.30482","article-title":"A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed\/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"123","author":"Milgrom","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clml.2016.09.008","article-title":"Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin's lymphoma with incomplete response before autologous stem cell transplantation","volume":"17","author":"Levis","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib43","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2017.01.222","article-title":"Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma: 20 Years of experience","volume":"97","author":"Rimner","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1083-8791(03)00205-2","article-title":"The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A southwest oncology group phase II trial","volume":"9","author":"Stiff","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: Analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdi003","article-title":"Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)","volume":"16","author":"Josting","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib48","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdf228","article-title":"The international prognostic factors project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation","volume":"13","author":"Bierman","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08616.x","article-title":"Autologous stem cell transplant for early relapsed\/refractory Hodgkin lymphoma: Results from two transplant centres","volume":"153","author":"Smith","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib51","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","article-title":"Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma","volume":"35","author":"Chan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/ehm.12.41","article-title":"The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant","volume":"5","author":"von Tresckow","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib53","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2013.88","article-title":"Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: Outcome after high-dose chemotherapy and auto-SCT","volume":"48","author":"Akhtar","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib54","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib55","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3109\/10428194.2011.573889","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib56","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib57","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1704759","article-title":"Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: A prospective Australasian Leukaemia and Lymphoma Group study","volume":"35","author":"Wirth","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib59","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjh.14898","article-title":"Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting","volume":"179","author":"Eyre","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2011.05.078","article-title":"Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy","volume":"83","author":"Fox","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2015.02.010","article-title":"Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: A comparison of second cancers and heart disease risk","volume":"92","author":"Filippi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib63","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","article-title":"Classical Hodgkin's lymphoma: The lymphoma study association guidelines for relapsed and refractory adult patients eligible for transplant","volume":"98","author":"Van Den Neste","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.12582","article-title":"Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma","volume":"164","author":"Collins","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib65","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib66","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin's lymphoma: An analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib67","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2007.15.5507","article-title":"Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma","volume":"26","author":"Goodman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib68","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.2013.53.2507","article-title":"Assessment of tumor size reduction improves outcome prediction of positron emission tomography\/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma","volume":"32","author":"Kobe","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib69","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.ijrobp.2005.05.006","article-title":"Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure","volume":"63","author":"Campbell","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib70","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib71","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","article-title":"Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espa\u00f1ol de Linfomas\/Transplante Aut\u00f3logo de M\u00e9dula Osea Spanish Cooperative Group","volume":"19","author":"Sureda","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib72","doi-asserted-by":"crossref","first-page":"968","DOI":"10.6004\/jnccn.2013.0117","article-title":"Targeted therapy in relapsed classical Hodgkin lymphoma","volume":"11","author":"Dinner","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib73","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17474086.2016.1242404","article-title":"Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: How they work and when to use them","volume":"9","author":"Savage","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.ijrobp.2018.01.011_bib74","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030161830049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030161830049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T11:19:02Z","timestamp":1603624742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030161830049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S036030161830049X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.011","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}